Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA ANDA APPROVALS DROPPED 48% IN OCTOBER

Executive Summary

FDA ANDA APPROVALS DROPPED 48% IN OCTOBER to 26 versus 50 approved in October 1987. The decline follows a similar one-month reduction of 44% in September ("The Pink Sheet" Oct. 3, p. 6). The numbers indicate that investigations by Rep. Dingell's (D-Mich.) House Oversight & Investigations Subcommittee and the HHS Inspector General's office into the approval practices of FDA's Generic Drug Division are taking a toll on the division's ability to process approvals. In a speech presented at the Sept. 28 meeting of the Regulatory Affairs Professionals Society, a generic division staffer acknowledged that there was a decline in September from the monthly approval average of 56.5. However, he attributed it to problems of quality in the ANDA applications being submitted to FDA. Since the investigation began in July, there have been a total of 163 ANDA approvals through October. During the same time span last year, a total of 199 ANDA applications were approved. FDA is currently looking for an acting supervisor for its ANDA Review Branch III. Branch chief Charles Chang, one of the targets in the generics investigation, is on temporary detail in FDA's Office of Regional Operations. The supervisory spot, which will be filled by a chemist from the branch, is an interim measure position.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS014596

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel